Cpg oligonucleotides

CpG oligonucleotides (CPG-ON) are a group of synthetically produced DNA oligonucleotides that contain a relatively high proportion of so-called CpG sequence motifs. The letter C stands for the nucleotide cytosine, p for phosphate and G for the nucleotide guanine.

The CpG sequence motif is rare in vertebrate DNA. Only about every 60th dinucleotide shows a CpG sequence motif. The innate immune system of vertebrates has a receptor, the Toll-like receptor 9, which is able to recognize CpG motifs in the DNA. TLR9 is mainly expressed by lymphocytes.

If a CpG motif is recognized by lymphocytes, a signaling cascade is triggered. For example, the receptor CD158k expressed on Sezary cells has been identified as a target structure for CpG oligonucleotides. CPG-ON cause an activation of CD158k, which leads to a dephosphorilization of the transcription factor STAT3 and finally to apoptosis.

A single CpG sequence motif always consists of six nucleobases, with the CG sequence (cytosine-guanosine) in the middle. The 2 neighboring nucleobases can be arbitrary. An example of a human sequence motif is: 5'..TCGTT..3' and 5'..TCGTA...3'. This sequence (motif) is repeated several times in a CpG oligonucleotide.

The targeted activation of TLR9 by CpG oligonucleotides opens up numerous therapeutic options (e.g. improving the effect of vaccines) and further applications are seen in cancer immunotherapy, in the treatment of infectious diseases or allergic diseases.

Oligodeoxynucleotides with the TTAGGGG sequence motif have the opposite effect to CpG oligonucleotides. They are TLR9 antagonists and have an immunosuppressive effect.

In 1984, T. Tokunaga was able to prove that the DNA fraction of Bacillus Calmette-Guérin (BCG) (BCG was administered as an adjuvant, also for the treatment of advanced malignant melanoma) was sufficient to activate NK cells (increase in interferon production; Note: after BCG therapy was abandoned, interferon therapy of malignant melanoma became the standard therapy). 10 years later, T. Tokunaga could prove that certain "palindrome sequences" (i.e. mirror-image sequences around a central dinucleotide) were responsible for this effect. Synthetically produced oligonucleotides with this motif show an analogous effect. Later it was found that a palindrome is not absolutely necessary for the immunogenic effect.

1. Gursel M et al (2016) Development of CpG ODN Based Vaccine Adjuvant Formulations. Methods Mol Biol. 1404:289-298.
2. Krieg AM et al (2000) Immune effects and therapeutic applications of CpG motifs in bacterial DNA. In: Immunopharmacology 48, pp. 303-305.
3. Krogmann AO et al (2016) Proinflammatory Stimulation of Toll-Like Receptor 9 with High Dose CpG ODN 1826 Impairs Endothelial Regeneration and Promotes Atherosclerosis in Mice. PLoS One. 11:e0146326.
4. Madathilparambil SV et al. (2016) Toll Like Receptor-9 (TLR9) is Requisite for Acute Inflammatory Response and Injury Following Lung Contusion. Shock PubMed PMID: 26939039.
5. Nicolay N et al (2016) The Sezary Syndrome: from unresolved questions to new approaches to therapy. JDDG 14: 256-265
6. Rotenfuß S et al (2001) CpG oligonucleotides: immunotherapy based on the pattern of bacterial DNA. German medical journal 98: 981-985.
7. Tokunaga T et al (1984) Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity J Natl Cancer Inst 72: 955-962.
8. S. Yamamoto S et al (1988) In vitro augmentation of natural killer cell activity and production of interferonalpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn J Cancer Res 79: 866-873.
9. Yamamoto S et al (192) DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol 36: 983-997.